Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Raymond James Life Sciences and MedTech Conference being held June 18-19 in New York, NY.
| Event: | Raymond James Life Sciences and MedTech Conference | |||||
| Date: | Tuesday, June 18 | |||||
| Time: | 1:15 p.m. ET | |||||
| Location: | New York, NY | |||||
The audio webcast of the presentation will be available live on the Wall Street Webcasting website at http://wsw.com/webcast/rj115/ayal/. The presentation will be accessible for 30 days.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102).
As a precision oncology company, Ayala was founded in November 2017 with an experienced global management team and a strong investor base. For more information, visit www.ayalapharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005617/en/
Contacts
Investors
Ayala Pharmaceuticals
+1-857-444-0553
info@ayalapharma.com
Media
Katie Dodge
+1-617-657-1304
kdodge@jpa.com
Source: Ayala Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190611005617/en
